Jakafi Safe and Effective in Polycythemia Vera

The results from a Phase III clinical trial indicate that Jakafi (ruxolitinib) controlled hematocrit levels and reduced spleen size by 35% or more among patients with polycythemia vera.

 Cancer Connect

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.